Immunic, Inc.
NASDAQ: IMUX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Vitt
- Employees
- 91
- Headquarters
- New York City, United States
- IPO year
- 2014
- Market cap
- $145.2M
- Website
- https://www.immunic-therapeutics.com
Loading IMUX…
Loading profile data…Frequently asked questions about IMUX
What does Immunic, Inc. (IMUX) do?
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS...
Where does IMUX trade?
Immunic, Inc. (IMUX) trades on the NASDAQ Global Select.
What sector is IMUX in?
Immunic, Inc. (IMUX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immunic, Inc.?
Daniel Vitt is the chief executive officer of Immunic, Inc. (IMUX).
Where is Immunic, Inc. headquartered?
Immunic, Inc. is headquartered in United States.
Does IMUX pay a dividend?
Immunic, Inc. (IMUX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMUX go public?
Immunic, Inc. (IMUX) completed its initial public offering in 2014.